{"nctId":"NCT00054717","briefTitle":"Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)","startDateStruct":{"date":"2003-01"},"conditions":["HIV Infections"],"count":630,"armGroups":[{"label":"Tipranavir(TPV)/low dose ritonavir(r)","type":"OTHER","interventionNames":["Drug: Tipranavir","Drug: Ritonavir(r)"]},{"label":"Comparator protease inhibitor(CPI)/low dose ritonavir(r)","type":"OTHER","interventionNames":["Drug: Ritonavir(r)","Drug: Comparator Protease Inhibitor (CPI)"]}],"interventions":[{"name":"Tipranavir","otherNames":[]},{"name":"Ritonavir(r)","otherNames":[]},{"name":"Comparator Protease Inhibitor (CPI)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPatients meeting the following criteria will be eligible for participation in th is study:\n\n1. Human Immunodeficiency virus 1 (HIV-1) infected males or females \\>=18 years of age.\n2. Screening genotypic resistance report indicating both of the following: at least one primary protease Inhibitor (PI) mutation at the following sites:\n\n30N, 46I/L, 48V, 50V, 82A/F/L/T, 84V or 90M, and no more than two protease mutations on codons 33, 82, 84, or 90.\n\n3\\. At least 3 consecutive months experience taking antiretrovirals (ARVs) from each of the classes of nucleoside reverse transcriptase inhibitors(NRTI(s)), non-nucleoside reverse transcriptase inhibitors(NNRTI(s)), and protease inhibitors (PIs) at some point in treatment history,with at least 2 protease inhibitor (PI)-based regimens, one of which must be the current regimen, and current protease inhibitor (PI)-based antiretroviral (ARV) medication regimen for at least 3 months prior to randomization.\n\n4\\. Human Immunodeficiency Virus 1 (HIV-1) viral load \\>=1,000 copies/mL at screening.\n\nExclusion criteria:\n\nPatients with any of the following criteria are excluded from participation in t he study:\n\n1. Antiretroviral (ARV) medication naïve.\n2. Patients on recent drug holiday, defined as off antiretroviral (ARV) medications for at least 7 consecutive days within the last 3 months.\n3. alanine aminotransferase (ALT) \\>=3.0x upper limit of normal (ULN) and aspartate aminotransferase(AST) \\>=2.5x upper limit of normal (ULN) (\\>=Division of AIDS(DAIDS) Grade 1) at either screening visit.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment Response at Week 48","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.80","spread":null},{"groupId":"OG001","value":"16.20","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to Treatment Failure Through 48 Weeks of Treatment","description":"Time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with VL measurements \\<1 log10 below baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 24","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.8","spread":null},{"groupId":"OG001","value":"23.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 2","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1","spread":null},{"groupId":"OG001","value":"34.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 4","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 8","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 16","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","spread":null},{"groupId":"OG001","value":"27.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 24","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","spread":null},{"groupId":"OG001","value":"23.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 32","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.9","spread":null},{"groupId":"OG001","value":"19.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 40","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":null},{"groupId":"OG001","value":"17.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 48","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","spread":null},{"groupId":"OG001","value":"16.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 56","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.5","spread":null},{"groupId":"OG001","value":"15.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 64","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"15.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 72","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":null},{"groupId":"OG001","value":"14.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 80","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"14.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 88","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","spread":null},{"groupId":"OG001","value":"12.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 96","description":"Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","spread":null},{"groupId":"OG001","value":"11.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Treatment Failure Through 96 Weeks of Treatment","description":"time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with VL measurements \\<1 log10 below baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Confirmed Virologic Failure Through 48 Weeks of Treatment","description":"Time to virologic failure is defined as the time from the start of treatment to the last measurement with a viral load reduction greater than 1.0 log before a confirmed drop of viral load reduction below 1.0 log.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Confirmed Virologic Failure Through 96 Weeks of Treatment","description":"Time to virologic failure is defined as the time from the start of treatment to the last measurement with a viral load reduction greater than 1.0 log before a confirmed drop of viral load reduction below 1.0 log.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (Viral Load >= 1 Log Drop) at Viral Load Nadir, LOCF","description":"Percentage of participants with Viral Load (VL) \\>= 1 log reduction from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.1","spread":null},{"groupId":"OG001","value":"50.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (Viral Load >= 1 Log Drop) at Week 2","description":"Percentage of participants with Viral Load (VL) \\>= 1 log reduction from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","spread":null},{"groupId":"OG001","value":"40.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (Viral Load >= 1 Log Drop) at Week 4","description":"Percentage of participants with Viral Load (VL) \\>= 1 log reduction from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","spread":null},{"groupId":"OG001","value":"40.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (Viral Load >= 1 Log Drop) at Week 8","description":"Percentage of participants with Viral Load (VL) \\>= 1 log reduction from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.9","spread":null},{"groupId":"OG001","value":"34.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (Viral Load >= 1 Log Drop) at Week 16","description":"Percentage of participants with Viral Load (VL) \\>= 1 log reduction from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.3","spread":null},{"groupId":"OG001","value":"26.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (Viral Load >= 1 Log Drop) at Week 24","description":"Percentage of participants with Viral Load (VL) \\>= 1 log reduction from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":null},{"groupId":"OG001","value":"22.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (Viral Load >= 1 Log Drop) at Week 32","description":"Percentage of participants with Viral Load (VL) \\>= 1 log reduction from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","spread":null},{"groupId":"OG001","value":"19.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (Viral Load >= 1 Log Drop) at Week 40","description":"Percentage of participants with Viral Load (VL) \\>= 1 log reduction from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.7","spread":null},{"groupId":"OG001","value":"17.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (Viral Load >= 1 Log Drop) at Week 48","description":"Percentage of participants with Viral Load (VL) \\>= 1 log reduction from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.3","spread":null},{"groupId":"OG001","value":"16.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (Viral Load >= 1 Log Drop) at Week 56","description":"Percentage of participants with Viral Load (VL) \\>= 1 log reduction from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null},{"groupId":"OG001","value":"15.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (Viral Load >= 1 Log Drop) at Week 64","description":"Percentage of participants with Viral Load (VL) \\>= 1 log reduction from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null},{"groupId":"OG001","value":"16.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in Viral Load to Week 2","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.36","spread":null},{"groupId":"OG001","value":"-0.57","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in Viral Load to Week 4","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.56","spread":null},{"groupId":"OG001","value":"-0.46","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in Viral Load to Week 8","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":null},{"groupId":"OG001","value":"-0.43","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in Viral Load to Week 16","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":null},{"groupId":"OG001","value":"-0.32","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in Viral Load to Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.81","spread":null},{"groupId":"OG001","value":"-0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in Viral Load to Week 32","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.73","spread":null},{"groupId":"OG001","value":"-0.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in Viral Load to Week 40","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":null},{"groupId":"OG001","value":"-0.23","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in Viral Load to Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":null},{"groupId":"OG001","value":"-0.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in Viral Load to Week 56","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":null},{"groupId":"OG001","value":"-0.23","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in Viral Load to Week 64","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":null},{"groupId":"OG001","value":"-0.23","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in Viral Load to Week 72","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.65","spread":null},{"groupId":"OG001","value":"-0.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in Viral Load to Week 80","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":null},{"groupId":"OG001","value":"-0.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in Viral Load to Week 88","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":null},{"groupId":"OG001","value":"-0.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in Viral Load to Week 96","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":null},{"groupId":"OG001","value":"-0.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 2 in CD4+ Cell Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":"48"},{"groupId":"OG001","value":"19","spread":"63"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 4 in CD4+ Cell Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":"69"},{"groupId":"OG001","value":"22","spread":"64"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 8 in CD4+ Cell Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":"72"},{"groupId":"OG001","value":"25","spread":"72"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 16 in CD4+ Cell Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":"92"},{"groupId":"OG001","value":"30","spread":"78"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 24 in CD4+ Cell Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":"86"},{"groupId":"OG001","value":"24","spread":"77"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 32 in CD4+ Cell Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":"91"},{"groupId":"OG001","value":"26","spread":"87"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 40 in CD4+ Cell Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":"100"},{"groupId":"OG001","value":"24","spread":"84"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 48 in CD4+ Cell Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":"95"},{"groupId":"OG001","value":"28","spread":"86"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 56 in CD4+ Cell Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":"104"},{"groupId":"OG001","value":"26","spread":"88"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 64 in CD4+ Cell Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":"107"},{"groupId":"OG001","value":"26","spread":"94"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 72 in CD4+ Cell Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":"113"},{"groupId":"OG001","value":"24","spread":"96"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 80 in CD4+ Cell Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":"122"},{"groupId":"OG001","value":"26","spread":"93"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 88 in CD4+ Cell Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":"126"},{"groupId":"OG001","value":"29","spread":"100"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 96 in CD4+ Cell Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":"133"},{"groupId":"OG001","value":"28","spread":"97"}]}]}]},{"type":"SECONDARY","title":"Time to New CDC Class C Progression Event or Death.","description":"Time to new Centers for Disease Control and Prevention (CDC) class C progression event (i.e., new AIDS defining illness) or death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"448","spread":null},{"groupId":"OG001","value":"284","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Viral Load Nadir, LOCF","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":null},{"groupId":"OG001","value":"32.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Week 2","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":null},{"groupId":"OG001","value":"13.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Week 4","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":null},{"groupId":"OG001","value":"19.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Week 8","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.3","spread":null},{"groupId":"OG001","value":"23.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Week 16","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7","spread":null},{"groupId":"OG001","value":"20.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Week 24","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.4","spread":null},{"groupId":"OG001","value":"16.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Week 32","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","spread":null},{"groupId":"OG001","value":"14.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Week 40","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","spread":null},{"groupId":"OG001","value":"14.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Week 48","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.5","spread":null},{"groupId":"OG001","value":"13.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Week 56","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":null},{"groupId":"OG001","value":"13.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Week 64","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":null},{"groupId":"OG001","value":"13.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Week 72","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":null},{"groupId":"OG001","value":"12.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Week 80","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"13.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Week 88","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"12.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 400 Copies/ml) at Week 96","description":"Percentage of participants with Viral Load \\< 400 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","spread":null},{"groupId":"OG001","value":"11.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Viral Load Nadir, LOCF","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.9","spread":null},{"groupId":"OG001","value":"20.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Week 2","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Week 4","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Week 8","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null},{"groupId":"OG001","value":"8.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Week 16","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"9.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Week 24","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Week 32","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Week 40","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"8.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Week 48","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":null},{"groupId":"OG001","value":"9.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Week 56","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Week 64","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.8","spread":null},{"groupId":"OG001","value":"10.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Week 72","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":null},{"groupId":"OG001","value":"11.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Week 80","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"10.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Week 88","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"9.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (VL < 50 Copies/ml) at Week 96","description":"Percentage of participants with Viral Load \\< 50 copies/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":null},{"groupId":"OG001","value":"9.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 Laboratory Abnormalities","description":"NIH Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"9.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":null},{"groupId":"OG001","value":"8.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.3","spread":null},{"groupId":"OG001","value":"15.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":113,"n":311},"commonTop":["Diarrhoea","Nausea","Fatigue","Upper respiratory tract infection","Vomiting"]}}}